US FDA’s Genetic Metabolic Diseases Adcomm Debuts With Zevra’s Arimoclomol
The Genetic Metabolic Diseases Adcomm is scheduled for its first meeting on 2 August, although the committee's standing members have not yet been announced. • Source: Shutterstock
